About NVIGEN
NVIGEN is a Healthcare company based in Sunnyvale (United States) founded in 2011. Nanoparticle research reagents devices for understanding, diagnosis and treatment of diseases. It operates in the Healthcare, Technology, and Chemicals & Materials sectors. NVIGEN has raised $2.23 million across 4 funding rounds from investors including NIH, HHS and Danen Ventures. The company has 8 employees. Its chief executive, as recorded, is Aihua Fu. NVIGEN offers products and services including NVIGEN Xâ„¢, MagVigenâ„¢, NERNST-Seqâ„¢, and On-Bead ELISA Kit. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
NVIGEN was established in 2011 in Sunnyvale, United States, within the biotechnology sector focused on nanomaterials. Operations center on the development and provision of nanoparticle reagents, such as magnetic and fluorescent magnetic beads, alongside services like antibody purification and immunoprecipitation assays. These offerings support research into disease understanding, diagnosis, and treatment, with activities conducted primarily in the U.S.
- Headquarters Sunnyvale, United States
- Employees 8
- SectorsHealthcareTechnology Chemicals & Materials
- Website nvigen.com
- Social LinkedIn X Facebook
- Legal Name Nvigen
- Total Equity Funding$2.23M (USD)
in 4 rounds
- Latest Funding Round$1.12M (USD), Seed
Mar 2014
- InvestorsNIH
& 4 more
- Employee Count8
Products & Services of NVIGEN
NVIGEN offers a comprehensive portfolio of products and services, including NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit.
NGS and multiomics test for early cancer recurrence prediction.
Tools for DNA extraction and purification in diagnostics.
Enhanced single cell RNA sequencing with spatial resolution.
Nanoparticle-based ELISA for sensitive protein biomarker detection.
Funding Insights of NVIGEN
NVIGEN has successfully raised a total of $2.23M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.12 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.23M
- Total Rounds 4
- Last Round Seed — $1.12M
- First Round $201,157
(Jun 2012)
- Investors Count 5
All 4 funding rounds of NVIGEN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | $1.12M | Seed | – | – | – |
| Feb 2014 | $1.12M | Seed | – | Danen Ventures, TSVC | – |
| Sep 2012 | $201,157 | Grant | – | – | |
| Jun 2012 | $201,157 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in NVIGEN
NVIGEN has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Danen Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| danenventures.com | ||||
Chinese venture fund in Silicon Valley | tsvcap.com | Los Altos, United States | ||
Investments are directed toward seed-stage startups by CRCM Ventures. | crcmventures.com | San Francisco, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for NVIGEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NVIGEN
4 people are tracked at NVIGEN (2 in leadership, 2 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Aihua Fu | CEO & President | Leadership |
Weiwei Gu | Director, Operation and Lab | Leadership |
Yanchun Li | Application Scientist | Team |
MINH TON | Manager of NGS Assays | Team |
Complete people profiles for NVIGEN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NVIGEN
3 dated milestones of NVIGEN across 3 years, from founding to its latest funding, stage changes and deals.
- Founded NVIGEN is founded.
- Funding First funding round of $201K.
- Funding Latest funding round, Seed, of $1.1M.
Competitors of NVIGEN
NVIGEN has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of NVIGEN
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NVIGEN
The website of NVIGEN (nvigen.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 6.8% vs previous month
Websites whose visitors overlap most with NVIGEN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as NVIGEN (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NVIGEN
NVIGEN was founded in 2011 and raised its 1st funding round 1 year after it was founded.
NVIGEN is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Aihua Fu is the CEO of NVIGEN, as recorded in our data.
NVIGEN is a funded company, having raised a total of $2.23M across 4 funding rounds to date. The company's 1st funding round was a Grant of $201.16K, raised on Jun 2012.
NVIGEN has 8 employees.
NVIGEN was established in 2011 in Sunnyvale, United States, within the biotechnology sector focused on nanomaterials. Operations center on the development and provision of nanoparticle reagents, such as magnetic and fluorescent magnetic beads, alongside services like antibody purification and immunoprecipitation assays. These offerings support research into disease understanding, diagnosis, and treatment, with activities conducted primarily in the U.S.
NVIGEN's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
NVIGEN offers NVIGEN Xâ„¢, MagVigenâ„¢, NERNST-Seqâ„¢, and On-Bead ELISA Kit.
NVIGEN has 5 investors. Key investors include NIH, HHS, Danen Ventures, TSVC, and CRCM Ventures.
NVIGEN operates through Nvigen.